Potential Biological Markers of Atrial Fibrillation: A Chance to Prevent Cryptogenic Stroke
Table 4
Markers with other functions.
Biomarker
Trials
Patients
Results
Potential DX efficiency in cryptogenic stroke
Circulating procoagulant microparticles
1 prospective trial
70
↑ PMPs in both AF patients and disease control subjects compared to healthy control subjects; ⦸ difference between AF patients and disease control subjects; ⦸ difference in PMP levels between patients with paroxysmal and permanent AF and between those receiving anticoagulant therapy
+
1 prospective trial
45
Circulating procoagulant MPs can be ↑ in persistent and/or permanent AF and might reflect a hypercoagulable state that could lead to atrial thrombosis and thromboembolism
ADMA
1 prospective trial
42
ADMA levels in patients with acute AF ↑ compared to patients with chronic AF and healthy controls
+
MicroRNA
1 prospective trial
10
The expression levels of these 4 miRNAs ↓ in patients with AF; the miRNA-150 levels ↓ by a factor of approximately 17 times in paroxysmal AF patients relative to controls and a factor of approximately 20 times in persistent AF relative to controls
+
1 prospective trial
2445
Circulating levels of miR-328 that were associated with prevalent AF adjustment for risk factors that promote atrial remodeling attenuated the association
